Inflammatory Bowel Diseases
Conditions
Keywords
Fecal Microbiota Transplantation
Brief summary
The human intestinal microbiota is composed of complex community of 10\*13 to 10\*14 commensal microorganisms\[1\]. Human intestine provides a nutrient-rich habitat for intestinal microorganism which allows a diverse ecosystem to enhance their host's immune system and facilitate digestive activities. Numerous researches are investigating the role of gut microbiota in human homeostasis, which may be related to the pathogenesis of gastrointestinal disease and autoimmune disorder. Fecal microbiota transplantation (FMT) is defined as infusion of feces from healthy donors to affected subjects. FMT works by altering the patient's microbiome and it is now recommended as an effective therapy for Clostridium difficile infection (CDI) not responding to standard therapies\[8\]. It has attracted great interest in recent years and many researches are exploring the FMT's potential role for treating other gastrointestinal disease such as IBD. A FMT registry is required to explore the relationship between disease prognosis and intestinal microbiota.
Detailed description
The human intestinal microbiota is composed of complex community of 10\*13 to 10\*14 commensal microorganisms\[1\]. Human intestine provides a nutrient-rich habitat for intestinal microorganism which allows a diverse ecosystem to enhance their host's immune system and facilitate digestive activities. Numerous researches are investigating the role of gut microbiota in human homeostasis, which may be related to the pathogenesis of gastrointestinal disease and autoimmune disorder. A research using gene-sequencing technique showed an abnormal microbiota composition such as specific group of Escherichia coli and decreased diversity of intestinal microbiota in individuals with Inflammatory Bowel Disease (IBD) \[2-4\]. These microbiotas may stimulate the production of cytokine and chemokines that leads to the mucosal inflammatory activity\[5\]. Gut microbiota may also link with the development of obesity and diabetes by affecting host fat storage and increasing energy harvest from the diet\[6-7\]. Fecal microbiota transplantation (FMT) is defined as infusion of feces from healthy donors to affected subjects. FMT works by altering the patient's microbiome and it is now recommended as an effective therapy for Clostridium difficile infection (CDI) not responding to standard therapies8. It has attracted great interest in recent years and many researches are exploring the FMT's potential role for treating other gastrointestinal disease such as IBD. A recent clinical study evaluated the efficacy of FMT in active Ulcerative Colitis. It showed one-forth cases of the FMT group were in UC remission and an increase in diversity of microbiota composition. However, these results were dependent on the donor\[9\]. There will be increasing use of FMT in clinical practice, as well as more studies investigating the effectiveness of FMT on other diseases in the future. However, as an emerging procedure, there is currently no registry system to track patient safety information of FMT. It is also equally important to promote scientific investigation around gut microbiome. Therefore, the investigators aim to establish a FMT registry platform to collect clinical data and specimen from FMT recipients and donors. This registry is initiated Hong Kong, and will be expanded to other part of Asia.
Interventions
None listed
Sponsors
Chinese University of Hong Kong
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Age ≥ 18 * Written informed consent obtained * Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research (FMT recipents) * Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research. Subjects who failed screening will also be recruited. (FMT donors)
Exclusion criteria
* Age ≤18
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Set up a FMT registry | 10 years | Set up a registry of FMT to collect data such as demographics, past medical history, surgery, severity of disease indicated for FMT cases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Factors associated with successful FMT | 10 years | Study samples will collected to characterize which microbiota favors FMT by performing metagenomics of gut microbiome in stool samples |
| Characterize FMT stool donors and other gut-related microbiota products | 10 years | Collect study samples to characterize which microbiota favors FMT by metagenomics |
| FMT in Asia | 10 years | Gather information such as the severity of disease, any adverse event related to FMT and hospitalization from other study sites in Asia. Survey |
| Patient outcome of FMT | 10 years | Compare the severity of disease, any adverse event related to FMT and hospitalization between baseline and FMT. Survey |
| Future research studies | 10 years | Number of patients who may be eligible for participation in future research studies by collecting their information demographics, past medical history, surgery, severity of disease |
| Developing Biobank of FMT | 10 years | Collect and store of study samples from recipients and donors to characterize which microbiota favors FMT by metagenomics |
| Promoting scientific investigation in FMT | 10 years | Collect study samples to characterize which microbiota favors FMT by metagenomics |
Countries
Hong Kong
Contacts
Primary ContactSiew Chien Ng, PhD
Outcome results
None listed